CYP2C19-related poor drug metabolism

CYP2C19-related poor drug metabolism is a condition in which the body is unable to properly process certain types of medications such as clopidogrel, mephenytoin, omeprazole, and/or proguanil. As a result, these medications are less effective in affected people who are treated with them. The condition is caused by changes (mutations) in the CYP2C19 gene and is inherited in an autosomal recessive manner. Specific treatment is generally not necessary as affected people do not have additional signs and symptoms aside from poor drug metabolism. However, medications that are poorly metabolized may need to be prescribed in a modified dose or avoided entirely.